Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day

Schizophrenia Research

Volumn 141, Issue 2-3, 2012, Pages 144-152

  Meltzer, Herbert Y ^a   Elkis, Helio ^b   Vanover, Kimberly ^c   Weiner, David M ^c   van Kammen, Daniel P ^c   Peters, Perry ^c   Hacksell, Uli ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c ACADIA PHARMACEUTICALS INC   (United States)

Author keywords

5 HT2A; Antipsychotic; Extrapyramidal; Haloperidol; Pimavanserin; Risperidone; Schizophrenia; Weight gain

Indexed keywords

HALOPERIDOL; PIMAVANSERIN; PLACEBO; RISPERIDONE;

ADULT; AGITATION; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; PAIN; PRIORITY JOURNAL; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT RESPONSE; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; FOLLOW-UP STUDIES; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; TIME FACTORS; UREA; YOUNG ADULT;

EID: 84866935453     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.07.029     Document Type: Article

References (78)

1. Addington D., Addington J., Schissel B. A depression rating scale for schizophrenics. Schizophr. Res. 1990, 3:247-251.
2. Agid O., Mamo D., Ginovart N., Vitcu I., Wilson A.A., Zipursky R.B., Kapur S. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response - a double-blind PET study in schizophrenia. Neuropsychopharmacology 2007, 32:1209-1215.
3. Akhondzadeh S., Malek-Hosseini M., Ghoreishi A., Raznahan M., Rezazadeh S.A. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1879-1883.
4. Albizu L., Holloway T., González-Maeso J., Sealfon S.C. Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors. Neuropharmacology 2011, 61:770-777.
5. Ancoli-Israel S., Vanover K.E., Weiner D.M., Davis R.E., Van Kammen D.P. Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers. Sleep Med. 2011, 12:134-141.
6. Anil Yagcioglu A.E., Kivircik Akdede B.B., Turgut T.I., Tümüklü M., Yazici M.K., Alptekin K., Ertugrul A., Jayathilake K., Gögüs A., Tunca Z., Meltzer H.Y. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J. Clin. Psychiatry 2005, 66:63-72.
7. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154:672-676.
8. Bonhaus D.W., Bach C., DeSouza A., Salazar F.H., Matsuoka B.D., Zuppan P., Chan H.W., Eglen R.M. The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. Br. J. Pharmacol. 1995, 115:622-628.
9. Buchanan R.W. Persistent negative symptoms in schizophrenia: an overview. Schizophr. Bull. 2007, 33:1013-1022.
10. Byne W., White L., Parella M., Adams R., Harvey P.D., Davis K.L. Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: prevalence and association with cognitive impairment. Int. J. Geriatr. Psychiatry 1998, 13:473-479.
11. Carlsson M.L., Martin P., Nilsson M., Sorensen S.M., Carlsson A., Waters S., Waters N. The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist-than dopamine agonist-induced hyperactivity in mice. J. Neural Transm. 1999, 106:123-129.
12. Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G.W., Labelle A., Beauclair L., Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 1993, 13:25-40.
13. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976, 192:481-483.
14. Dean C.E., Thuras P.D. Mortality and tardive dyskinesia: long-term study using the US National Death Index. Br. J. Psychiatry 2009, 194:360-364.
15. Erritzoe D., Rasmussen H., Kristiansen K.T., Frokjaer V.G., Haugbol S., Pinborg L., Baaré W., Svarer C., Madsen J., Lublin H., Knudsen G.M., Glenthoj B.Y. Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients. Neuropsychopharmacology 2008, 33:2435-2441.
16. Fribourg M., Moreno J.L., Holloway T., Provasi D., Baki L., Mahajan R., Park G., Adney S.K., Hatcher C., Eltit J.M., Ruta J.D., Albizu L., Li Z., Umali A., Shim J., Fabiato A., MacKerell A.D., Brezina V., Sealfon S.C., Filizola M., González-Maeso J., Logothetis D.E. Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 2011, 147:1011-1023.
17. Gardell L.R., Vanover K.E., Pounds L., Johnson R.W., Barido R., Anderson G.T., Veinbergs I., Dyssegaard A., Brunmark P., Tabatabaei A., Davis R.E., Brann M.R., Hacksell U., Bonhaus D.W. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. J. Pharmacol. Exp. Ther. 2007, 322:862-870.
18. ECDEU assessment manual for psychopharmacology Rev Rockville: Alcohol, Drug Abuse, and Mental Health Administration. DHEW publication no (ADM) 1976, 76-338:217-222. W. Guy (Ed.).
19. Harvey P.D., Bellack A.S. Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept?. Schizophr. Bull. 2009, 35:300-306.
20. Honer W.G., Thornton A.E., Chen E.Y., Chan R.C., Wong J.O., Bergmann A., Falkai P., Pomarol-Clotet E., McKenna P.J., Stip E., Williams R., MacEwan G.W., Wasan K., Procyshyn R. Clozapine and Risperidone Enhancement (CARE) Study Group. N. Engl. J. Med. 2006, 354:472-482.
21. Horiguchi M., Huang M., Meltzer H.Y. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J. Pharmacol. Exp. Ther. 2011, 338:605-614.
22. 2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. Psychopharmacology (Berl) 2011, 217:13-24.
23. Hugenholtz G.W., Heerdink E.R., Stolker J.J., Meijer W.E., Egberts A.C., Nolen W.A. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J. Clin. Psychiatry 2006, 67:897-903.
24. Ichikawa J., Li Z., Dai J., Meltzer H.Y. Atypical APDs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. 2002, 956:349-357.
25. Kalkstein S., Hurford I., Gur R.C. Neurocognition in schizophrenia. Curr. Top. Behav. Neurosci. 2010, 4:373-390.
26. Kapur S., Seeman P. Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am. J. Psychiatry 2001, 158:360-369.
27. Kapur S., Remington G., Zipursky R.B., Wilson A.A., Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci. 1995, 57:103-107.
28. Kapur S., Remington G., Jones C., Wilson A., DaSilva J., Houle S., Zipursky R. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am. J. Psychiatry 1996, 153:948-950.
29. Kapur S., Zipursky R., Roy P., Jones C., Remington G., Reed K., Houle S. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology (Berl) 1997, 131:148-152.
30. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 2000, 157:514-520.
31. Kay S.R., Fiszbein A., Opler L. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr. Bull. 1987, 13:261-276.
32. Keshavan M.S., Nasrallah H.A., Tandon R. Neurocognition in schizophrenia. Schizophr. Res. 2011, 127:3-13.
33. Kinon B.J., Chen L., Ascher-Svanum H., Stauffer V.L., Kollack-Walker S., Zhou W., Kapur S., Kane J.M. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 2010, 35:581-590.
34. Kroeze W.K., Hufeisen S.J., Popadak B.A., Renock S.M., Steinberg S., Ernsberger P., Jayathilake K., Meltzer H.Y., Roth B.L. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical APDs. Neuropsychopharmacology 2003, 28:519-526.
35. Lee M.A., Jayathilake K., Meltzer H.Y. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr. Res. 1999, 37:1-11.
36. Leucht S., Wahlbeck K., Hamann J., Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2000, 361:1581-1589.
37. Li Z., Ichikawa J., Dai J., Meltzer H.Y. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur. J. Pharmacol. 2004, 16(493):75-83.
38. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of APDs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223.
39. Lüttgen M., Ogren S.O., Meister B. 5-HT1A receptor mRNA and immunoreactivity in the rat medial septum/diagonal band of Broca-relationships to GABAergic and cholinergic neurons. J. Chem. Neuroanat. 2005, 29:93-111.
40. Maier W., Mössner R., Quednow B.B., Wagner M., Hurlemann R. From genes to psychoses and back: the role of the 5HT2alpha-receptor and prepulse inhibition in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2008, 258(Suppl. 5):40-43.
41. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry 1994, 151:825-835.
42. Margolese H.C., Chouinard G., Kolivakis T.T., Beauclair L., Miller R., Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Can. J. Psychiatry 2005, 50:703-714.
43. Martin P., Waters N., Carlsson A., Carlsson M.L. The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. J. Neural Transm. 1997, 104:561-564.
44. McEvoy J.P., Stiller R.L., Farr R. Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study. J. Clin. Psychopharmacol. 1986, 6:133-138.
45. McEvoy J.P., Hogarty G.E., Steingard S. Optimal dose of neuroleptic in acute schizophrenia.A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch. Gen. Psychiatry 1991, 48:739-745.
46. Meltzer H.Y. An atypical compound by any other name is still an atypical. Psychopharmacology 2000, 148:16-19.
47. Meltzer H.Y., Bobo W.V. Interpreting the efficacy findings in the CATIE study: what clinicians should know. CNS Spectr. 2006, 11(7 Suppl.):14-24.
48. Meltzer H.Y., Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res. 2008, 172:177-197.
49. Meltzer H.Y., Matsubara S., Lee J.C. Classification of typical and atypical APDs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 1989, 251:238-246.
50. Meltzer H.Y., Li Z., Kaneda Y., Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:1159-1172.
51. Meltzer H.Y., Arvanitis L., Bauer D., Rein W. Meta-Trial Study Group Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiatry 2004, 161:975-984.
52. Meltzer H.Y., Bobo W.V., Lee M.A., Cola P., Jayathilake K. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia. Psychiatry Res. 2010, 177:286-293.
53. Meltzer H.Y., Mills R., Revell S., Williams H., Johnson A., Bahr D., Friedman J.H. Neuropsychopharmacology 2010, 35:881-892.
54. Meltzer H.Y., Bonaccorso S., Bobo W.V., Chen Y., Jayathilake K. A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. J. Clin. Psychiatry. 2011, 72(12):1602-1610.
55. Meltzer H.Y., Horiguchi M., Massey B.W. The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology (Berl) 2011, 213:289-305.
56. Meltzer H.Y., Massey B.W., Horiguchi M. Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. Curr. Pharm. Biotechnol. 2012, 13:1572-1586.
57. Miller A.L., Crismon M.L., Rush A.J., Chiles J., Kashner T.M., Toprac M., Carmody T., Biggs M., Shores-Wilson K., Chiles J., Witte B., Bow-Thomas C., Velligan D.I., Trivedi M., Suppes T., Shon S. The Texas medication algorithm project: clinical results for schizophrenia. Schizophr. Bull. 2004, 30:627-647.
58. Moreno J.L., Kurita M., Holloway T., López J., Cadagan R., Martínez-Sobrido L., García-Sastre A., González-Maeso J. Maternal influenza viral infection causes schizophrenia-like alterations of 5-HT2A and mGlu2 receptors in the adult offspring. J. Neurosci. 2011, 31:1863-1872.
59. Morrato E.H., Cuffel B., Newcomer J.W., Lombardo I., Kamat S., Barron J. Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients. J. Clin. Psychopharmacol. 2009, 29:26-32.
60. Nocjar C., Roth B.L., Pehek E.A. Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group. Neuroscience 2002, 111:163-176.
61. Nordstrom A.L., Mansson M., Jovanovic H., Karlsson P., Halldin C., Farde L., Vanover K.E., Hacksell U., Brann M.R., Davis R.E., Weiner D.M. PET analysis of the 2A receptor inverse agonist ACP-103 in human brain. Int. J. Neuropsychopharmacol. 2008, 11:163-171.
62. Nyberg S., Nordström A.L., Halldin C., Farde L. Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man. Int. Clin. Psychopharmacol. 1995, 10(Suppl. 3):81-85.
63. Nyberg S., Eriksson B., Oxenstierna G., Halldin C., Farde L. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am. J. Psychiatry 1999, 156:869-875.
64. Potkin S.G., Saha A.R., Kujawa M.J., Carson W.H., Ali M., Stock E., Stringfellow J., Ingenito G., Marder S.R. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 2003, 60:681-690.
65. Potkin S.G., Cohen M., Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo-and risperidone-controlled trial. J. Clin. Psychiatry 2007, 68:1492-1500.
66. Preda A., Nguyen D., Macciardi F., McMillan L., Bunney W.E., Potkin S.G. D2 receptor occupancy is not required for antipsychotic response in schizophrenia: A randomized clinical trials with M100907, a 5HT2A antagonist. Personal Communication 2011, (Dec), (Jan 5, 2012).
67. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference APDs: in vitro and in vivo receptor binding. Psychopharmacology 1996, 124:57-73.
68. Schreiber R., Brocco M., Millan M.J. Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone. Eur. J. Pharmacol. 1994, 264(1):99-102.
69. Simon V., Van Winkel R., De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J. Clin. Psychiatry 2009, 70:1041-1050.
70. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212:11-19.
71. Snigdha S., Horiguchi M., Huang M., Li Z., Shahid M., Neill J.C., Meltzer H.Y. Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical APDs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. J. Pharmacol. Exp. Ther. 2010, 332:622-631.
72. Tiihonen J., Lönnqvist J., Wahlbeck K., Klaukka T., Niskanen L., Tanskanen A., Haukka J. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009, 374:620-627.
73. Uchida H., Takeuchi H., Graff-Guerrero A., Suzuki T., Watanabe K., Mamo D.C. Predicting dopamine D2 receptor occupancy from plasma levels of APDs: a systematic review and pooled analysis. J. Clin. Psychopharmacol. 2011, 31:318-325.
74. Vanover K.E., Weiner D.M., Makhay M., Veinbergs I., Gardell L.R., Lameh J., Del Tredici A.L., Piu F., Schiffer H.H., Ott T.R., Burstein E.S., Uldam A.K., Thygesen M.B., Schlienger N., Andersson C.M., Son T.Y., Harvey S.C., Powell S.B., Geyer M.A., Tolf B.R., Brann M.R., Davis R.E. Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N(1-methylpiperidin-4-yl)-N'-(4-(2methylpropyloxy)phenylmethyl)Carbamine (2R,3R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine 2A Receptor Inverse Agonist. J. Pharmacol. Exp. Ther. 2006, 317:910-918.
75. Velligan D.I., Weiden P.J., Sajatovic M., Scott J., Carpenter D., Ross R., Docherty J.P. Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J. Clin. Psychiatry 2009, 70(Suppl. 4):1-46.
76. Weiner D.M., Vanover K.E., Brann M.R., Meltzer H.Y., Davis R.E. Psychosis of Parkinson's disease: serotonin 2A receptor inverse agonists as potential therapeutics. Curr. Opin. Investig. Drugs 2003, 4:815-819.
77. Wiesel F.A., Nordström A.L., Farde L., Eriksson B. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology (Berl) 1994, 114:31-38.
78. Zimbroff D.L., Kane J.M., Tamminga C.A., Daniel D.G., Mack R.J., Wozniak P.J., Sebree T.B., Wallin B.A., Kashkin K.B. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am. J. Psychiatry 1997, 154:782-791.